Skip to main content

Table 5 Maximum reduction in the sum of lesions and a single lesion after samalizumab dosing

From: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Samalizumab Treatment Group Patient ID Single Lesionb Sum of Lesionsb
% Change Cycle Day % Change Cycle Day
50 mg/m2 (N = 4) 101–103 −3.45 C1 D28 2.77 C1 D28
101–104 −45.29 C1 D77 −9.8 C1 D35
102–101 −19.75 C4 D16 4.32 C4 D16
102–102 −9.77 C1 D35 −9.46 C1 D35
100 mg/m2 (N = 4)a 101–202 −37.78 C4 D0 −6.83 C4 D0
101–203 −11.54 C4 D0 7.0 C1 D28
102–201 −95.31 C4 D0 −20.7 C4 D0
102–205 −41.36 C3 D26 −18.7 C3 D26
200 mg/m2 (N = 2)a 101–301 − 48.67 C1 D28 −28.7 C1 D28
102–303 −42.05 C3 D21 −4.75 C3 D21
300 mg/m2 (N = 3) 101–402 −14.29 C4 D43 8.3 C4 D43
101–403 −23.81 C1 D29 −12.5 C1 D29
102–401 −58.73 C1 D35 −16.1 C16 D1
400 mg/m2 (N = 3) 102–502 −87.02 C13 D35 −63.4 C13 D35
107–503 −54.55 C4 D27 −3.34 C1 D42
107–504 −29.34 C1 D29 9.52 C1 D29
500 mg/m2 (N = 4)a 101–606 −48.15 C6 D0 −6.91 C6 D0
102–601 −86.36 C2 D28 −73.7 C2 D28
102–603 −5.13 C1 D25 1.84 C1 D25
102–607 −37.36 C1 D28 −19.4 C1 D28
  1. aPatient 107–602 (500 mg/m2 cohort) did not have a post-dose CT scan and was not evaluable; Patients 104–204 (100 mg/m2 cohort) and 104–302 (200 mg/m2 cohort) had no reduction in any of their target lesions and are not included
  2. bMaximum reduction for a single lesion (product of bi-dimensional tumor measurement) and maximum reduction for sum of lesions (sum of the products of bi-dimensional tumor measurements) are presented as a % Change from baseline on the indicated Cycle and Day